secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001628280-22-027190
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive licenses Sympazan to Assertio for $9M upfront; up to $6M milestone
----------------------------------------------------------------------------

- Exclusive worldwide license of Sympazan (clobazam) oral film to Otter Pharmaceuticals (Assertio) for LGS.
- Aquestive receives $9M upfront and will get $6M milestone upon patent allowance (notice already received Oct 27, 2022).
- Aquestive will also receive royalties from Assertio and serve as exclusive manufacturer under long-term supply agreement.
- Deal provides non-dilutive financing to focus on development of AQST-109 (epinephrine sublingual film) for anaphylaxis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/0001628280-22-027190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/aqst-20221026.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer